槐杞黄颗粒辅助贝利尤单抗治疗儿童SLE的疗效及不良反应  

Study on Effect and Adverse Reaction of Huaiqihuang Granule Assisted Beliuzumab in SLE Treatment Among Children

作　　者：赵静丽 李天坡 陈朴 吴琼 牛文忠[1] 赵丽丽[1] 郑大炜[1] Zhao Jingli;Li Tianpo;Chen Pu(Department of Pediatrics,Nanyang Central Hos pital,Henan Province,Nanyang 473000,China;Department of Pediatrics,Nanyang Hospital of Traditional Chinese Medicine,Henan Province,Nanyang 473007,China)

机构地区：[1]河南省南阳市中心医院儿科,南阳473000 [2]河南省南阳市中医院儿科,南阳473007

出　　处：《华中科技大学学报(医学版)》2024年第6期808-813,共6页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

基　　金：河南省医学科技攻关计划联合共建项目(No.20-21ZY2298)。

摘　　要：目的探究槐杞黄颗粒辅助贝利尤单抗治疗儿童系统性红斑狼疮(SLE)的疗效及不良反应。方法选取2020年7月~2023年7月南阳市中心医院收治的100例SLE患儿,采用简单随机化法分为对照A组(n=33)、对照B组(n=33)和研究组(n=34)。3组均行常规治疗,在此基础上,给予对照A组贝利尤单抗治疗,给予对照B组槐杞黄颗粒治疗,给予研究组槐杞黄颗粒+贝利尤单抗治疗,均治疗24周。比较3组治疗效果、症状改善情况、治疗前后血清免疫指标[免疫球蛋白G(IgG)、补体C3、补体C4、CD3^(+)T细胞占比、CD4^(+)/CD8^(+)]、炎症指标[白介素-2(IL-2)、血沉(ESR)、C反应蛋白(CRP)]、微小RNA-200(miR-200)、微小RNA-335(miR-335)水平,并统计比较3组治疗期间不良反应。结果研究组总有效率为97.06%,与对照A组(81.82%)、对照B组(78.79%)比较,差异无统计学意义(均P>0.05);研究组皮损减轻时间、蛋白尿降低时间、疼痛减轻时间、体温下降时间短于对照A组、对照B组(均P<0.05);治疗24周后,研究组血清补体C3、补体C4、外周血CD3^(+)T细胞占比、CD4^(+)/CD8^(+)水平高于对照A组、对照B组,IgG水平低于对照A组、对照B组(均P<0.05);研究组治疗24周后血清IL-2、CRP、外周血ESR水平低于对照A组、对照B组(均P<0.05);研究组治疗24周后血清miR-200水平高于对照A组、对照B组,血清miR-335水平低于对照A组、对照B组(均P<0.05);研究组、对照A组、对照B组不良反应发生率分别为8.82%、12.12%、6.06%,组间比较差异无统计学意义(均P>0.05)。结论槐杞黄颗粒辅助贝利尤单抗治疗儿童SLE的疗效显著,能更有效增强免疫功能,且安全性良好。Objective To investigate the efficacy of Huaiqihuang Granules assisted Beliuzumab in the treatment of children with systemic lupus erythematosus(SLE)and its adverse reaction.Methods A total of 100 children with SLE,who were admitted to Nanyang Central Hospital between July 2020 and July 2023,were selected.They were randomly assigned to control group A(n=33),control group B(n=33),and study group(n=34)according to simple randomization method.All three groups received conventional treatment.In addition,control group A was treated with belimumab,control group B was treated with Huaiqihuang Granules,and the study group was treated with Huaiqihuang Granules+belimumab.All patients were treated for 24 weeks.The therapeutic effects and symptom improvement of the three groups were compared,as well as the levels of serum immune indicators[immunoglobulin G(IgG),complement C3,complement C4,CD3^(+),CD4^(+)/CD8^(+)],inflammatory factors[interleukin-2(IL-2),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)],microRNA-200(miR-200),microRNA-335(miR-335)before and after treatment.The adverse reactions during treatment were statistically compared among the three groups.Results The difference in total effective rate between the study group(97.06%),control group A(81.82%)and control group B(78.79%)was not significant(all P>0.05).The study group showed a shorter time for skin lesion reduction,proteinuria decrease,pain relief,and body temperature drop compared to the control A and B groups(all P<0.05).After 24 weeks of treatment,the levels of serum complement C3,complement C4,peripheral blood CD3^(+),and CD4^(+)/CD8^(+)in the study group were higher than those in control group A and B.Meanwhile,the level of IgG was lower(all P<0.05).After 24 weeks of treatment,the levels of serum IL-2,CRP,and peripheral blood ESR in the study group were lower than those in control group A and B(all P<0.05).After 24 weeks of treatment,the serum miR-200 level in the study group was higher than that in control group A and B,while the serum miR-335

关 键 词：系统性红斑狼疮 儿童 槐杞黄颗粒 贝利尤单抗 免疫功能 安全性 

分 类 号：R593.2[医药卫生—内科学] R725.9[医药卫生—临床医学]